Structure-activity relationships in a series of orally active γ- hydroxy butenolide endothelin antagonists

Journal of Medicinal Chemistry

Volumn 40, Issue 7, 1997, Pages 1063-1074

  Patt, William C ^a   Edmunds, Jeremy J ^a   Repine, Joseph T ^a   Berryman, Kent A ^a   Reisdorph, Billy R ^a   Lee, Chet ^a   Plummer, Mark S ^a   Shahripour, Aurash ^a   Haleen, Stephen J ^a   Keiser, Joan A ^a   Flynn, Mike A ^a   Welch, Kathleen M ^a   Reynolds, Elwood E ^a   Rubin, Ron ^a   Tobias, Brian ^a   Hallak, Hussein ^a   Doherty, Annette M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; BUTENOLIDE DERIVATIVE; PD 012527; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; DOG; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMORAL ARTERY; NONHUMAN; RABBIT; STRUCTURE ACTIVITY RELATION; VASCULAR SMOOTH MUSCLE;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; DIOXOLES; DOGS; ENDOTHELIN-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; RABBITS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 14444282863     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9606507     Document Type: Article

References (59)

1. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332, 411-415.
2. Rubanyi, G.; Polokoff, M. Endothelins: Molecular Biology, Biochemistry, Pharmacology, Physiology, and Pathophysiology, Pharmacol. Rev. 1994, 46, 325-415.
3. Cheng, X.-M.; Nikam, S.; Doherty, A. Development of Agents to Modulate the Effects of Endothelin. Curr. Med. Chem. 1994, 1, 271-312.
4. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 2863-2867.
5. Watanabe, T.; Suzuki, N.; Shimamoto, N.; Fujino, M.; Imada, A. Endothelin in myocardial infarction. Nature 1990, 344, 114.
6. Cosentino, F.; Katusic, Z. S. Does Endothelin-1 play a role in the pathogenesis of cerebral vasospasm? Stroke 1994, 25, 904-908.
7. Patel, T.; Galbraith, S.; McAuley, M.; Doherty, A.; Graham, D.; McCulloch, J. Therapeutic potential of endothelin receptor antagonists in experimental stroke. J. Cardiovasc. Pharmacol. 1995, 26 (Suppl. 3), S412-S415.
8. Takahashi, K.; Totsune, K.; Mouri, T. Endothelin in chronic renal failure. Nephron 1994, 66, 373-379.
9. Saito, Y.; Nakao, K.; Mukoyama, M.; Imura, H. Increased plasma endothelin level in patients with essential hypertension. N. Engl. J. Med. 1989, 322, 205.
10. Teerlink, J.: Loeffler, B.-M.; Hess, P.; Maire, J.-P.; Clozel, M.; Clozel, J.-P. Role of the endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994, 90, 2510-2518.
11. Giaid, A.; Yanagisawa, M.; Langleben, D.; Michel, R.; Levy, R.; Shennib, H.; Kimura, S.; Masaki, T.; Duguid, W.; Path, F. R. C.; Stewart, D. J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1993, 328, 1732-1739.
12. Douglas, S.; Louden, C.; Vickery-Clark, L.; Storer, B.; Hart, T.; Feuerstein, G.; Elliott, J.; Ohlstein, E. A role for endogenous endothelin-1 in neointima formation following rat carotid artery ballon angioplasty: antiproliferative effects of the non-peptide endothelin receptor antagonist SB 209670. Circ. Res. 1994, 75, 190-197.
13. Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanishi, S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348, 730-732.
14. Sakurai, T.; Yanagisawa, M.; Takuwa, Y.; Miyazaki, H.; Kimura, S.; Goto, K.; Masaki, T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348, 732-735.
15. Sakamoto, A.; Yanagisawa, M.; Sakurai, T.; Takuwa, Y.; Yanagisawa, H.; Masaki, T. Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem. Biophys. Res. Commun. 1991, 178, 656-663.
16. Hosoda, K.; Nakao, K.; Arai, H.; Suga, S.; Ogawa, Y.; Mukoyama, M.; Shirakami, G.; Saito, Y.; Nakanishi, S.; Imura, H. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett. 1991, 287, 23-26.
17. Yoneyama, T.; Hori, M.; Makatani, M.; Yamamura, T.; Tanaka, T.; Matsuda, Y.; Karaki, H. Subtypes of endothelin ETA and ETB receptors mediating traceal smooth muscle contraction. Biochem. Biophys. Res. Commun. 1995, 207, 668-674.
18. Karne, S.; Jayawickreme, C. K.; Lerner, M. R. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J. Biol. Chem. 1993, 268, 19126-19133.
19. Clozel, M.; Gray, G. A.; Breu, V.; Loffler, B.-M.; Osterwalder, R. The endothelin ETC receptor mediates both vasodilatation and vasoconstriction in vivo. Biochem. Biophys. Res. Commun. 1992, 186, 867-873.
20. Sumner, M. J.; Cannon, T. R.; Mundin, J. W.; White, D. G.; Watts, I. S. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br. J. Pharmacol. 1992, 107, 858-860.
21. Moreland, S.; McMullen, D. M.; Delaney, C. L.; Lee, V. G.; Hunt, J. T. Venous smooth muscle contains vasoconstrictor ETB like receptors. Biochem. Biophys. Res. Commun. 1992, 184, 100-106.
22. Godfraind, T. Endothelin receptors in human coronary artery. Trends Pharmacol. Sci. 1994, 15, 136.
23. Davenport, A. P.; Maguire, J. J. Endothelin receptors in human coronary artery-reply. Trends Pharmacol. Sci. 1994, 15, 136-137.
24. Tschudi, M. R.; Luscher, T. F. Characterization of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem. Biophys. Res. Commun. 1994, 204, 685-690.
25. Seo, B.; Oemar, B. S.; Siebenmann, R.; Von Segesser, L. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994, 89, 1203-1208.
26. White, D. G.; Garratt, H.; Mundin, J. W.; Sumner, M. J.; Vallance, P. J.; Watt, I. S. Human saphenous vein contains both endothelin ETA and ETB contractile receptors. Eur. J. Pharmacol. 1994, 257, 307-310.
27. Bax, W. A.; Bos, E.; Saxena, P. R. Heterogeneity of endothelin/ sarafotoxin receptors mediating contraction of the human saphenous vein. Eur. J. Pharmacol. 1993, 239, 267-268.
28. Sudjarwo, S. A.; Hori, M.; Tanaka, T.; Matsuda, Y.; Okada, T.; Karaki, H. Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contraction. Biochem. Biophys. Res. Commun. 1994, 200, 627-633.
29. Ishikawa, K.; Fukami, T.; Nagase, T.; Fujita, K.; Hayama, T.; Niyama, K.; Mase, T.; Ihara, M.; Yano, M. Cyclic pentapeptide endothelin antagonists with ETA selectivity. Potency and solubility enhancing modifications. J. Med. Chem. 1992, 35, 2139-2142.
30. Ihara, M.; Noguchi, K.; Saeki, T.; Fukuroda, T.; Tsuchida, S.; Kimura, S.; Fukami, T.; Ishikawa, K.; Nishikibe, M.; Yano, M. Biological profiles of highly potent novel endothelin antagonists selective for ETA receptor. Life Sci. 1992, 50, 247-255.
31. Sogabe, K.; Nirei, H.; Shoubo, M.; Nomoto, A.; Ao, S.; Notsu, Y.; Ono, T. Pharmacological profile of FR 139317, a novel, potent endothelin ETA receptor antagonist. J. Pharmacol. Exp. Ther. 1993, 264, 1040-1046.
32. Cody, W. L.; Doherty, A. M.; He, J. X.; DePue, P. M.; Rapundalo, S. T.; Hingorani, G. A.; Major, T. C.; Panek, R. L.; Haleen, S.; LaDouceur, D.; Reynolds, E. E.; Hill, K. E.; Flynn, M. A. Design of a functional antagonist of endothelin. J. Med. Chem. 1992, 35, 3301-3303.
33. Cody, W. L.; Doherty, A. M.; He, J. X.; DePue, P. L.; Waite, L. A.; Topliss, J. G.; Haleen, S. J.; LaDouceur, D.; Flynn, M. A.; Hill, K. E.; Reynolds, E. E. The rational design of a highly potent combined ETA and ETB receptor antagonist. Med. Chem. Res. 1993, 3, 154-162.
34. Ishikawa, K.; Ihara, M.; Noguchi, K.; Mase, T.; Mino, N.; Saeki, T.; Fukuroda, T.; Fukami, T.; Ozaki, S.; Nagase, T.; Nishikibe, J.; Yano, M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist BQ-788. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4892-4896.
35. Clozel, M.; Breu, V.; Burri, K.; Cassao, J.-M.; Fischli, W.; Gray, G. A.; Hirth, G.; Loffler, B.-M.; Muller, M.; Neidhart, W.; Ramuz, H. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993, 365, 759-761.
36. Roux, S. P.; Clozel, M.; Sprecher, U.; Gray, G.; Clozel, J. P. Ro 47-0203, a new endothelin receptor antagonist reverses chronic vasospasm in experimental subarachnoid hemorrhage. Circulation 1993, 88, I-170.
37. Elliott, J. D.; Lago, M. A.; Cousins, R. D.; Gao, A.; Leber, J. D.; Erhard, K. F.; Nambi, P.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Bean, J. W.; DeBrosse, C. W.; Eggleston, D. S.; Brooks, D. P.; Feuerstein, G.; Ruffolo, R. R.; Weinstock, J.; Gleason, J. G.; Peishoff, C. E.; Ohlstein, E. H. 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists. J. Med. Chem. 1994, 37, 1553-1557.
38. Mugrage, B.; Moliterni, J.; Robinson, L.; Webb, R. L.; Shetty, S. S.; Lipson, K. E.; Chin, M. H.; Neale, R.; Cioffi, C. CGS 27830, a potent nonpeptide endothelin receptor antagonist. Bioorg. Med. Chem. Lett. 1993, 3, 2099-2104.
39. Walsh, T. F.; Fitch, K. J.; Chakravarty, K.; Williams, D. L.; Murphy, K. A.; Nolan, N. A.; O'Brien, J. A.; Lis, E. V.; Pettibone, D. J.; Kivlighn, S. D.; Gabel, R. A.; Zingaro, G. J.; Krause, S. M.; Siegl, P. K. S.; Clineschmidt, B. V.; Greenlee, W. J. Discovery of L-749,329, a highly potent, orally active antagonist of endothelin receptors. ACS National meeting, Washington, August 1994, MEDI 145.
40. Stein, P. D.; Hunt, J. T.; Floyd, D. M.; Moreland, S.; Dickinson, K. E. J.; Mitchell, C.; Liu, E. C.-K.; Webb, M. L.; Murugesan, N.; Dickey, J.; McMullen, D.; Zhang, R.; Lee, V. G.; Serafino, R.; Delaney, C.; Schaeffer, T. R.; Kozlowski, M. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide. J. Med. Chem. 1994, 37, 329-331.
41. Doherty, A.; Patt, W.; Edmunds, J.; Berryman, K.; Reisdorph, B.; Plummer, M.; Shahripour, A.; Lee, C.; Cheng, X.-M.; Walker, D.; Haleen, S.; Keiser, J.; Flynn, M.; Welch, K.; Hallak, H.; Taylor, D.; Reynolds, E. Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. J. Med. Chem. 1995, 38, 1259-1263.
42. Winn, M.; von Geldern, T.; Opgenorth, T.; Jae, H.-S.; Tasker, A.; Boyd, S.; Kester, J.; Mantei, R.; Bal, R.; Sorenson, B.; Wu-Wong, J.; Chiou, W.; Dixon, D.; Novosad, E.; Hernandez, L.; Marsh, K. 2,4-Diarylpyrolidine-3-carboxylic acids-potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J. Med. Chem. 1996, 39, 1039-1048.
43. Wu, C.; Raju, B.; Okun, I.; Stavros, F.; Chan, M. 2-Benzylcarbonylthiophene-3-sulfonamides are orally active ETA selective endothelin antagonists. Book of Abstracts, 211th ACS National Meeting, New Orleans, LA, March 24-28, 1996, MEDI-148.
44. Riechers, H.; Albrecht, H.-P.; Amberg, W.; Baumann, E.; Bernard, H.; Bohm, H.-J.; Klinge, D.; Kling, A.; Muller, S.; Raschack, M., Unger, L.; Walker, N,; Wernet, W. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J. Med. Chem. 1996, 39, 2123-2128.
45. Allen C. F. H.; Frame, G. F. The condensation of certain γ-ketonic esters with aromatic aldehydes. Can. J. Res. 1932, 605-613.
46. 2O.
47. Gribble, G.; Leese, R. Reaction of sodium borohydride in acidic media; IV. Reduction of diarylmethanols and triarylmethanols in trifluoroacetic acid. Synthesis 1977, 3, 172-176.
48. 16]. Bioorg. Med. Chem. Lett. 1993, 3 (4), 497-502.
49. Doherty, A. M.; Cody, W. L.; He, J. X.; DePue, P. L.; He, J. X.; Wiate, L. A.; Leonard, D. M.; Leitz, N. L.; Dudley, D. T.; Rapundalo, S. T.; Hingorani, G. P.; Haleen, S. J.; LaDouceur, D. M.; Hill, K. E.; Flynn, M. A.; Reynolds, E. E. Structure-Activity relationships of C-terminal endothelin hexapeptide antagonists. J. Med. Chem. 1993, 36, 2585-2594.
50. Reynolds, E. E.; Keiser, J. A.; Haleen, S. J.; Walker, D. M.; Davis, L. S.; Olszewski, B.; Taylor, D. G.; Hwang, O.; Welch, K. M.; Flynn, M. A.; Thompson, D. M.; Edmunds, J. J.; Berryman, K. A.; Lee, C.; Reisdorph, B. R.; Cheng, X. M.; Patt, W. C.; Doherty, A. M. Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist. J. Pharmacol. Exp. Ther. 1994, 273, 1410-1417.
51. Reynolds, E. E.; Mok, L. L. Phorbol ester dissociates endothelin-stimulated phosphoinositide hydrolysis and arachidonic acid release in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 1989, 160, 868-873.
52. Doherty, A.; Cody, W.; He, J.; DePue, P.; Leonard, D.; Dunbar, J.; Hill, K.; Flynn, M.; Reynolds, E. Design of C-terminal peptide antagonists of endothelin: Structure-activity relationships of ET-1[16,21, D-His]. Bioorg. Med. Chem. Lett. 1993, 3, 497-502.
53. Panek, R. L.; Major, T. C.; Hingorani, G. P.; Doherty, A. M.; Taylor, D. G.; Rapundalo, S. T. Endothelin and structurally related analogues distinguish between endothelin receptor subtypes. Biochem. Biophys. Res. Commun. 1992, 183, 566-571.
54. Doherty, A. M.; Cody, W. L.; He, J. X.; DePue, P. L.; Cheng, X.-M.; Welch, K. M.; Flynn, M. A.; Reynolds, E. E.; LaDouceur, D. M.; Davis, L. S.; Keiser, J. A.; Haleen, S. J. In vitro and in vivo studies with a series of hexapepide endothelin antagonists. J. Cardiovasc. Pharmacol. 1993, 22 (Suppl. 8), S98-S102.
55. Topliss, J. G. Utilization of Operational Schemes for analogue synthesis in drug design. J. Med. Chem. 1972, 15, 1006-1011.
56. Topliss, J. G. A manual method for applying the Hansch approach to drug design. J. Med. Chem. 1977, 20, 463-469.
57. Doherty, A.; Patt, W.; Reisdorph, B.; Repine, J.; Walker, D.; Flynn, M.; Welch, K.; Reynolds, E.; Haleen, S. Design and pharmacological evaluation of a series of non-peptide endothelin ETA selective and ETA/ETB receptor antagonists. In Medicinal Chemistry: Today and Tomorrow. Proceedings of the AFMC International Medicinal Chemistry Symposium (AIMECS 95), Tokyo (Japan): September 3-8, 1995; Yamazaki, M., Ed.; Blackwell Science Ltd.: London, 1996; pp 255-261.
58. Repine, J.; Patt, W.; Flynn, M.; Welch, K.; Reynolds, E.; Haleen, S.; Hussein, H.; Doherty, A. Gamma-Butenolide derivatives which function as human endothelin antagonists. Book of Abstracts, 212th ACS National Meeting, Orlando, FL, August 25-29, 1996, MEDI-171.
59. Compound 1 was tested in a variety of standard assays by Panlabs, Inc.